Paper Details

  1. Home
  2. Paper Details

Efficacy and safety of daratumumab in the treatment of relapsed/refractory multiple myeloma: A meta-analysis of randomized controlled trials.

Author: HanHan, HuangZeng-Yi, JinXiao-Qin, LiangQi-Lian, WangZhen-Wei, ZhangDing-Yue

Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Daratumumab-based regimens were effective in treating relapsed/refractory multiple myeloma, improving progression-free survival, minimal residual disease, and overall response rate. However, these regimens also increased the risk of pneumonia, upper respiratory tract infections, and diarrhea.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Daratumumab as a monoclonal antibody has shown promising results in the treatment of relapsed/refractory multiple myeloma (RRMM). However, the efficacy and safety of daratumumab-based regimens compared to control regimens have not been fully established. METHODS: The search was conducte...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10519573/

データ提供：米国国立医学図書館（NLM）

Daratumumab: A Promising Treatment for Relapsed/Refractory Multiple Myeloma

This study investigates the efficacy and safety of daratumumab, a monoclonal antibody, in the treatment of relapsed/refractory multiple myeloma (RRMM). The researchers conducted a meta-analysis of randomized controlled trials to assess the effectiveness of daratumumab-based regimens compared to standard therapies.

Their analysis revealed that daratumumab-based regimens significantly improved progression-free survival, overall response rate, and minimal residual disease (MRD) compared to control regimens. However, the study also identified an increased risk of pneumonia, upper respiratory tract infections, and diarrhea in patients receiving daratumumab.

New Hope for Multiple Myeloma Patients

The study's findings offer a glimmer of hope for patients with RRMM. Daratumumab-based therapies have shown promising results in improving patient outcomes, but careful consideration of potential side effects is essential.

Navigating the Treatment Landscape for Multiple Myeloma

The study underscores the importance of personalized medicine and careful risk-benefit assessments when choosing treatment options for RRMM. The potential benefits of daratumumab must be weighed against the risks of potential side effects.

Dr.Camel's Conclusion

This study provides a comprehensive evaluation of daratumumab's efficacy and safety in treating RRMM. The research highlights the potential benefits of this antibody therapy while acknowledging the need for careful monitoring and personalized management strategies.

Date :
  1. Date Completed 2023-09-26
  2. Date Revised 2023-10-08
Further Info :

Pubmed ID

37747011

DOI: Digital Object Identifier

PMC10519573

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.